For survivors of spontaneous intracerebral haemorrhage (ICH) — one of the most lethal and disabling forms of stroke — the question of how aggressively to lower blood pressure afterward has long been contested. This individual participant data (IPD) meta-analysis from The Lancet Neurology offers the most statistically granular answer yet, pooling trial-level data at the patient level rather than relying on aggregate study-level estimates, a methodological step up that allows meaningful subgroup analyses rarely possible in conventional meta-analyses.
The RECAP-ICH collaboration systematically identified randomized controlled trials from Embase and MEDLINE through January 2026, restricting inclusion to adults with confirmed spontaneous ICH randomized to either fixed-dose antihypertensive regimens or intensive, titrated blood pressure targets versus placebo or standard care. By pooling individual-level data across diverse geographic and clinical settings, the analysis was designed to quantify not only the average treatment effect on major cardiovascular endpoints — including recurrent stroke — but also its consistency across clinically relevant subgroups and the temporal trajectory of benefit accrual. The excerpt does not disclose full effect sizes, but the framing of a halved recurrent stroke risk is consistent with leading trials in this space such as PROGRESS and SPS3.
This work carries significant practical weight. ICH survivors face a recurrent stroke risk estimated at 2–5% per year, disproportionately driven by hypertension, yet clinical inertia around aggressive pressure control has persisted partly because of concerns about cerebral perfusion and heterogeneity of benefit across ICH subtypes (lobar versus deep). The IPD design here allows subgroup interrogation — by hemorrhage location, severity, age, and baseline pressure — that aggregate analyses obscure. If consistent benefit is confirmed across subgroups, it would meaningfully strengthen guideline recommendations to pursue intensive rather than standard blood pressure targets post-ICH. Key limitations will hinge on the number of eligible trials, total participant count, and follow-up duration, none yet fully disclosed in the available excerpt. As a systematic IPD review in a top-tier journal, this represents a potentially practice-clarifying contribution rather than merely incremental evidence.